ALNYLAM PHARMACEUTICALS, INC. Revenue, Net (Deprecated 2018-01-31)
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Revenue, Net (Deprecated 2018-01-31) of $20.90 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-05.
Discontinued › Income Statement › Revenue
us-gaap:SalesRevenueNet · last filed 2011-05-05
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2011-03-31 was $20.90M, a 14.93% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2010-12-31 was $21.19M, a 20.41% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2010-09-30 was $27.67M, a 14.10% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for the quarter ending 2010-06-30 was $26.62M, a 8.19% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for fiscal 2010 was $100.04M, a 0.49% decline from fiscal 2009.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for fiscal 2009 was $100.53M, a 4.54% increase from fiscal 2008.
- ALNYLAM PHARMACEUTICALS, INC. revenue, net (deprecated 2018-01-31) for fiscal 2008 was $96.16M.
| Period end | Revenue, Net (Deprecated 2018-01-31) 3 month | Revenue, Net (Deprecated 2018-01-31) 6 month | Revenue, Net (Deprecated 2018-01-31) 9 month | Revenue, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2011-03-31 | $20.90M 10-Q · filed 2011-05-05 | $42.09M derived: sum of 2 quarters · filed 2011-05-05 | $69.76M derived: sum of 3 quarters · filed 2011-05-05 | $96.37M derived: sum of 4 quarters · filed 2011-05-05 |
| 2010-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $48.86M derived: sum of 2 quarters · filed 2011-02-18 | $75.48M derived: sum of 3 quarters · filed 2011-02-18 | $100.04M 10-K · filed 2011-02-18 |
| 2010-09-30 | $27.67M 10-Q · filed 2010-11-04 | $54.28M derived: sum of 2 quarters · filed 2010-11-04 | $78.85M 10-Q · filed 2010-11-04 | $105.47M derived: sum of 4 quarters · filed 2011-05-05 |
| 2010-06-30 | $26.62M 10-Q · filed 2010-08-05 | $51.18M 10-Q · filed 2010-08-05 | $77.81M derived: sum of 3 quarters · filed 2011-05-05 | $102.06M derived: sum of 4 quarters · filed 2011-05-05 |
| 2010-03-31 | $24.56M 10-Q · filed 2011-05-05 | $51.19M derived: sum of 2 quarters · filed 2011-05-05 | $75.44M derived: sum of 3 quarters · filed 2011-05-05 | $100.04M derived: sum of 4 quarters · filed 2011-05-05 |
| 2009-12-31 | $26.63M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $50.88M derived: sum of 2 quarters · filed 2011-02-18 | $75.48M derived: sum of 3 quarters · filed 2011-02-18 | $100.53M 10-K · filed 2011-02-18 |
| 2009-09-30 | $24.25M 10-Q · filed 2010-11-04 | $48.85M derived: sum of 2 quarters · filed 2010-11-04 | $73.91M 10-Q · filed 2010-11-04 | |
| 2009-06-30 | $24.60M 10-Q · filed 2010-08-05 | $49.66M 10-Q · filed 2010-08-05 | ||
| 2008-12-31 | $96.16M 10-K · filed 2011-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |